Diabetic Macular Edema | Epidemiology | Emerging Markets Data

Publish date: January 2018

Login to access report
DRG Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of DME for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s DME forecast answers the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with DME?
Of all people with DME, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with DME, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DME over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following DME subpopulations:
Diagnosis status.
Treatment status.
Note: Coverage may vary by country and region.

Table of contents

  • Emerging Markets Data
    • Introduction
      • Key Findings
      • Total Prevalence of Diabetic Macular Edema per 1,000 People Aged 20+ in 2018 and 2028
      • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Diabetic Macular Edema over the Next Ten Years
      • Analysis of Total Prevalent Cases of Diabetic Macular Edema in 2018 by Severity of Diabetic Retinopathy
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases
      • Severity
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Fjoralba Kristo, MD, MPH; Lade Ayodele

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods. Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.

Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets. Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.